ABT vs IBIO · P/E 25, rev $44.33B vs rev $100.0K
Abbott Laboratories (ABT) versus iBio, Inc. Common Stock (IBIO) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
iBio, Inc. Common Stock (IBIO) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported IBIO revenue for 2026-06-30 was $100.0K. Net income was -$32.8M. Revenue was down 75.0% from 2025-06-30 to 2026-06-30. IBIO currently screens at market cap $13.4M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. IBIO currently screens at market cap $13.4M.
Not investment advice. Open the ABT and IBIO stock pages for the full models.
Not investment advice.